In the News
Syngene enters pact with GSK to provide drug discovery services
Money Control-27/03/2018. As part of the agreement, Syngene will set-up a customized discovery research laboratory to support projects across several therapeutic areas.
Focus on growth, investments; capacity in Biologics a growth driver: Syngene Intl
Money Control-24/01/2018. With a focus on future business growth, the company has done lot of investments – building new infrastructure and capabilities and they are now ready, said Hunt...
We are in the process of implementing a $200 million growth capex plan to expand capacity and extend capabilities
Globally, we anticipate to see a healthy demand for high quality scientific services, not just in the pharma and biotechnology industries but also in other research focused industries...
Bristol-Myers Squibb, Syngene International Expand Ongoing Research Collaboration
Outook-14/11/2017. Syngene will set up a new dedicated facility spread across 25,000 sq. ft. of laboratory and office space for Bristol-Myers Squibb...
Expect good momentum to continue in H2FY18: Syngene CEO
Money Control-26/10/2017. The revenues for Syngene in the second quarter (July-September) were up 10.6 percent at Rs 334.2 crore versus Rs 303 crore for the...
Syngene expands Amgen collaboration as it recovers from fire incident
Outsourcing Pharma-31/07/2017. Syngene International is doubling the footprint of its research and development center....
Company on a path of recovery; Q1 has been solid: Manoj Nerurkar, Syngene International
Economic Times-28/07/2017. Clearly we are on a recovery path, we believe we made a significant progress going from minus 6% to plus 6% in terms of revenue growth ...
Aim to get back to around 20% revenue growth in FY18: Syngene
Money Control-28/04/2017. The tie-up with the Canadia Company is a good start for the biologics business...
Initiator Pharma selects Syngene and Research Toxicology Centre (RTC) as primary partners for the preclinical development of IPED2015.
Cision News-19/04/2017. Initiator Pharma has selected Syngene, India and Research Toxicology Centre, Italy ( RTC) as contract research organizations (CROs) to conduct the pre-clinical development of the drug candidate IPED2015 for the treatment of ED.
Biologics and Biosimilars -Promising field for medicines for the future by Dr. Dhananjay Patankar (Head-Pharmaceutical and Biopharmaceutical Development)
Pharma Focus Asia-09/03/2017. As per Make in India campaign by the government, Indian biotech industry, comprising bio pharmaceuticals, is expected to grow at a rate of 30 per cent a year and reach US$100 billion by 2025.
- March 2018 (1)
- January 2018 (2)
- November 2017 (2)
- October 2017 (1)
- August 2017 (1)
- July 2017 (1)
- May 2017 (1)
- March 2017 (3)
- February 2017 (1)
- November 2016 (1)
- September 2016 (2)
- July 2016 (1)
- April 2016 (1)
- February 2016 (1)
- January 2016 (3)
- November 2015 (1)
- October 2015 (3)
- September 2015 (3)
- August 2015 (2)
- June 2015 (1)